Qiagen NV (WBO:QGE2)
€ 40.8 -0.54 (-1.31%) Market Cap: 9.01 Bil Enterprise Value: 9.48 Bil PE Ratio: 137.61 PB Ratio: 2.86 GF Score: 87/100

Qiagen NV at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 03:30PM GMT
Release Date Price: €45.08 (-1.95%)
Tycho W. Peterson
JPMorgan Chase & Co, Research Division - Senior Analyst

All right. Good morning, everybody. I'm Tycho Peterson. It's my pleasure to introduce our next company this morning, QIAGEN. (Operator Instructions)

And with that, I'll turn it over to Thierry.

Thierry Bernard
QIAGEN N.V. - CEO, MD & Member of Management Board

Thank you, Tycho, and thank all of you. Good morning or good afternoon, depending on where you are. Thanks for your interest on QIAGEN. Obviously, a very happy and a very healthy New Year to all of you.

I'm very pleased and honored to present to you once again on QIAGEN at JPMorgan 2 years after our change of management end of 2019. 2 years during which I believe our company has definitely proven to be extremely COVID relevant, but absolutely not COVID-dependent, and 2 years from which I believe as well that our company emerges as a stronger, as a more focused QIAGEN.

I'm going to drive that presentation, a signal when I'm moving from slide-to-slide.

Moving to Slide 3. For those who

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot